MUDr. Aleš Langer; MUDr. Hana Študentová, Ph.D.

Onkologická klinika LF UP a FN Olomouc



Niraparib is younger member of PARP inhibitors family. Some PARP inhibitors are used in treatment of ovarian carcinoma routinely. This carcinoma is the most lethal of all Gynecological carcinomas. Incidence of this cancer is slightly decreasing, but it is still one of the most common cancers leading to death in women worldwide. The ovarian carcinomas are often diagnosed in an advanced clinical stage 3 or 4. Ovarian cancer is usually sensitive to platinum and taxane based chemotherapy, but treatment resistance and relapses develop throughout the disease course. Niraparib works as a maintenance therapy in a recurrent ovarian carcinoma. Niraparib provides the best results in BRCA1/2 mutated patients.


Key words

PARP, PARP inhibitors, niraparib, BRCA1, BRCA2, ovarian carcinoma



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...